Measurements
ADCS/ADL [
Patients and their caregivers were assessed at baseline (T0), after eight weeks of treatment (T1), and after 12 months after the baseline (T2) by a neuropsychologist blinded to the patient’s assignment to groups (ABILITY vs. TAU). Both patients and caregivers were asked about the usability of the ABILITY technology for home settings. Patients were evaluated individually with a neuropsychological battery, autonomy in daily living, and behavioral symptoms, as detailed below.Efficiency Output Measures: the System Usability Scale (SUS; [Patients Neuropsychological Assessment: the Montreal Cognitive Assessment (MoCA [Output and outcome measurements.MoCA: Montreal Cognitive Assessment [Autonomy in daily living and behavioral symptoms: the level of autonomy in daily living was evaluated through the Activities of Daily Living Inventory (ADCS/ADL [